164 research outputs found
Inclusion and exclusion criteria, methodological flaw and ethical concepts for the treatment of patients with ocular Behçet disease
No full text
The migration pattern, patient selection with diagnostic methodological flaw and confusing naming dilemma in Behcet disease
No full textManaging the symptoms of Behcet's disease
No full textBehcet's disease (BD) is a chronic, relapsing, systemic inflammatory vasculitis of unknown aetiology with a myriad of immunological and pathological consequences. Patients with BD are clustered along the ancient silk road, extending from Far-East Asia to Turkey. The disease affects both genders of all ages from infants to the elderly. It is a long-term, cyclical disease and such patients may have symptom-free periods of weeks, months or years that are interrupted by exacerbations of varying intensities lasting a few days, weeks or months. Clinical features include oral aphthae, genital ulcers, ocular inflammation, skin lesions, as well as articular, vascular, neurological, pulmonary, gastrointestinal, renal and genitourinary manifestations. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size or thrombophilia according to the site of involvement. BD may start with just one or two small symptoms but other symptoms may gradually appear over the years. Recurrent ocular inflammation, which occurs in similar to 50% of cases, is the major morbidity that may eventually lead to blindness. The treatment of BD is usually symptomatic and palliative. Therefore, the main objectives are to relieve symptoms associated with mucocutaneous lesions and arthritis, to modify the course of the disease, to control inflammatory eye disease, clinically suppress the inflammation and vasculitis, to prevent recurrences and thus, prevent irreversible damage. The choice of treatment is based on the severity of systemic involvement, clinical presentation and the site affected. The preferred treatment modalities are combined drug therapy and include topical therapies as well as systemic corticosteroids, NSAIDs, colchicine, dapsone and immunosuppressive and cytotoxic agents. Such therapies are tailored to the individual patient depending on clinical manifestations. Thalidomide, tacrolimus, IFN-alpha and anti-TNF monoclonal antibody have recently attracted attention as novel therapeutic approaches
Diagnostic dilemma between intestinal Behcet disease and inflammatory bowel disease with pyoderma gangrenosum
No full text
Behcet disease: from naming heterogeneity to the historical evolution of an antique silk-road disease
No full textBehcet's disease or Adamantiades-Behcet disease? An evidence-based historical survey
No full textBackground: The aim is to inform authors, investigators, and journal editors about the evolution and progression of Behcet symptoms or findings chronologically in evidence-based historical articles since Hippocratic writings to bring physicians with different areas of interest to a consensus and thus address the significance of consistency in the eponym "Behcet" among authors interested in Behcet's disease care and research, as science does not accept a "naming dilemma"
'Kite-tail' fascia lata strips technique: frontalis suspension using a non-endoscopic minimally invasive single-thigh incision approach
No full textAim To introduce 'kite-tail' strips or a 'multiple Z-plasty' technique on an autogenous fascia lata graft without a stripper to correct severe blepharoptosis by frontalis suspension and to evaluate its effectiveness on surgical outcome
- …
